SC
GMAB icon

Schubert & Co’s Genmab GMAB Stock Holding History

Schubert & Co’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-83
Closed -$3.13K – 632
2023
Q1 		$3.13K Sell
83
-8
-9% -$308 ﹤0.01% 688
2022
Q4 		$3.86K Buy
91
+1
+1% +$41 ﹤0.01% 541
2022
Q3 		$3K Buy
90
+9
+11% +$316 ﹤0.01% 613
2022
Q2 		$3K Buy
+81
New +$2.62K ﹤0.01% 588

Other funds holding GMAB

AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
1832 Asset Management
1832 Asset Management Toronto, Ontario, Canada $109B AUM 35.56% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Schubert & Co's GMAB Position: Q2 2023 in Review

Schubert & Co sold out of Genmab (GMAB) in Q2 2023, closing a stake of 83 shares — an estimated $3.13K sold.

Schubert & Co first reported a position in GMAB in Q2 2022 and held it in 4 quarters. The position peaked at $3.86K in Q4 2022. 213 funds tracked by Wall St. Rank hold GMAB as of Q2 2023.

  • Schubert & Co reported no remaining Genmab position as of Q2 2023 after selling out during the quarter.
  • Schubert & Co sold 83 Genmab shares in Q2 2023, an estimated $3.13K.
  • Schubert & Co first reported a position in Genmab in Q2 2022 and held it in 4 quarters.
  • Schubert & Co's Genmab position peaked at $3.86K in Q4 2022.
  • 213 funds tracked by Wall St. Rank held Genmab as of Q2 2023.

Based on Schubert & Co's 13F filing for Q2 2023, filed 4 Aug 2023.